Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Ad-CEA vaccine plus avelumab vs mFOLFOX6-based standard care in untreated metastatic CRC

Jason Redman • 3 Jul 2020
ESMO WCGIC 2020
Colorectal Cancer Gastrointestinal Cancer Ad-CEA Antibodies Avelumab mFOLFOX6

Jason Redman, MD, National Cancer Institute, Bethesda, MD, discusses the randomized Phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Jason Redman

3:03
QuEST1 clinical trial updates
Jason Redman • 23 Sep 2020
1:40
Anti-PD-L1/TGF-β trap in non-HPV associated HNSCC
Jason Redman • 24 Jun 2020

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals